EYPT

Amended: EyePoint Pharma Appoints Ramiro Ribeiro As New CMO To Succeed Dario Paggiarino

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT) Monday said it has appointed Ramiro Ribeiro as its new Chief Medical Officer, to succeed Dario Paggiarino who has been serving as its CMO since 2016.

Ribeiro has been working with Apellis Pharmaceuticals as the vice president of clinical development.

In pre-market activity, EyePoint Pharma shares were trading at $28.36, up 1.29% on the Nasdaq.

(Amended: Following clarification from the company, headline and intro have been changed to mean Dario Paggiarino did not quit.)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.